ArticleFrontiers in bioengineering and biotechnology2026
AAV capsid sites breakdown: large protein insertions impact on vector dynamics.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Adeno-associated virus (AAV) vectors are one of the most used gene delivery systems, and several capsid engineering strategies have been followed to further improve their performance. Current capsid design approaches predominantly rely on small peptide insertions (<100 a.a.). Integrating large proteins poses challenges due to the nature of protein folding and the complexity of capsid assembly. Methods: This study seeks to explore capsid engineerable hotspots for large protein insertion, aiming to unlock the use of AAV vectors to deliver large protein cargo and extend their use beyond traditional AAV gene therapy approaches. In this work, we employed a capsid mosaic approach, integrating a mCherry protein (236 a.a) into the VP1 capsid protein (453 or 587 residues) and the N-terminal of VP2 (corresponding to 138 residue of VP1). A systematic breakdown of the different capsid insertions was performed to elucidate insertion site versatility and behaviour. Results and Discussion: The engineered AAV2/mCherry mosaic vectors presented no major impairments in biophysical and particle functionality. Moreover, alterations in particle titer or biophysical properties were associated with the development of mosaic vectors, rather than the mCherry insertion. In vitro transduction studies showed residues 138 and 453 as particularly permissive sites for functional protein integration without severe structural or functional compromises. While still affecting mCherry fluorescence, both sites preserved the protein's activity more than site 587. Our work unveils the robustness of AAV capsids to host substantial domain insertions without compromising particle production. The characterisation of these particles ultimately indicated that residue 138 is the most flexible site for inserting proteins up to 236 amino acids, followed by residue 453. These findings establish foundational knowledge for broadening the applications of these vectors to deliver large protein cargo, paving the way for the future development of novel AAV vector systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.